Compare FLEX & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLEX | NTRA |
|---|---|---|
| Founded | 1990 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.9B | 39.1B |
| IPO Year | 1997 | 2015 |
| Metric | FLEX | NTRA |
|---|---|---|
| Price | $122.63 | $265.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 15 |
| Target Price | $66.89 | ★ $259.07 |
| AVG Volume (30 Days) | ★ 4.7M | 1.0M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.43 | 0.65 |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $28,679,925,000.00 | $210,939,000.00 |
| Revenue This Year | $8.14 | $18.08 |
| Revenue Next Year | $6.28 | $19.65 |
| P/E Ratio | $161.86 | ★ N/A |
| Revenue Growth | ★ 18.95 | N/A |
| 52 Week Low | $47.83 | $149.50 |
| 52 Week High | $166.86 | $288.04 |
| Indicator | FLEX | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 44.54 | 55.05 |
| Support Level | $111.38 | $261.63 |
| Resistance Level | $131.68 | $288.04 |
| Average True Range (ATR) | 7.48 | 10.37 |
| MACD | 0.82 | -0.58 |
| Stochastic Oscillator | 57.02 | 66.22 |
Flex Ltd is the developed, end-to-end manufacturing partner of choice that helps a diverse customer base design, build, deliver and manage products that improve the world. The Company's full suite of specialized capabilities includes design and engineering, supply chain, manufacturing, and integrated services, plus a portfolio of power and cooling products. Its reportable segments includes Integrated Technology Solutions, Regulated Manufacturing Solutions, and Cloud and Power Infrastructure.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.